Medical Affairs Capabilities to Create a Competitive Advantage with Tamas Suto, MD, PhD

Leading Medical Affairs (MA) organizations have begun to strategically redefine their team's requisite executional capabilities to enhance and tailor frontline engagement initiatives, to improve the impact of knowledge development (insights and evidence generation), and to further solidify their position as a vital leader rather than a support function within the biopharmaceutical industry. These executional capabilities ultimately accelerate the time to market, creating a competitive advantage as well as (and most importantly) maximizes the number of patients reached with life-saving treatments. Dr. Tamas Suto is passionately dedicated to improving the lives of patients and public health as evidenced by his decades in not only direct patient care, but also in industry spanning the commercialization process from identification of a drug candidate through the end of the lifecycle of a compound. His extensive experience in large pharma as a global executive in MA leadership at Sanofi, Amgen, and Roche/Genentech prior to his current position as SVP., & Head of Global MA Oncology at Merck KGaA, Darmstadt, Germany underpins his well-founded and impressive vision of the critical capabilities of the MA team. Dr. Peg Crowley-Nowick, Founder and President of Zipher Medical Affairs, guides Dr. Suto in this podcast in sharing the paramount yet foundational competencies for impactful individual contributions in each of the four key elements of the MA team pursuits: insights, evidence generation, stakeholder engagement, and medical leadership.